Evaluating the real-life effect of MP-AzeFlu on asthma control in patients with allergic rhinitis and asthma in UK primary care

Hilda de Jong, Ruth Murray, Victoria Carter, Dermot Ryan, Glenis Scadding, Walter Canonica, Pete Smith, Ulrich Wahn, Jose Antonio Castillo, Claus Bachert, David Price

Research output: Contribution to journalAbstract

Abstract

Background
MP-AzeFlu (azelastine/fluticasone propionate in one spray) is the most effective allergic rhinitis (AR) treatment available. Its effect on asthma control in co-morbid patients is unknown. We examined whether MP-AzeFlu altered asthma control in patients with AR and asthma.
Original languageEnglish
JournalAllergy
Publication statusAccepted/In press - 8 Jun 2020
EventEAACI Digital Congress 2020 - Digital, London, United Kingdom
Duration: 6 Jun 20208 Jun 2020

Fingerprint Dive into the research topics of 'Evaluating the real-life effect of MP-AzeFlu on asthma control in patients with allergic rhinitis and asthma in UK primary care'. Together they form a unique fingerprint.

  • Cite this

    de Jong, H., Murray, R., Carter, V., Ryan, D., Scadding, G., Canonica, W., Smith, P., Wahn, U., Castillo, J. A., Bachert, C., & Price, D. (Accepted/In press). Evaluating the real-life effect of MP-AzeFlu on asthma control in patients with allergic rhinitis and asthma in UK primary care. Allergy.